Sarzi-Puttini P, et al. - The CZP-SPEED study was a 52-week, open-label, prospective, interventional, multicenter study which evaluated the effect of certolizumab pegol (CZP) treatment on clinical, patient-reported, and musculoskeletal ultrasound outcomes as well as determined the treatment response time point most predictive of long-term outcomes in Italian patients with rheumatoid arthritis (RA). Results of this study suggested that week 12 clinical responses might be predictive of long-term response at week 52 in Italian CZP-treated patients with moderate-to-severe RA. Findings revealed that rapid improvements in clinical, patient-reported, and musculoskeletal ultrasound outcomes were maintained to week 52. No progression in cartilage damage or bone erosion, as well as no new safety signals, were identified. The authors suggested that this information might help rheumatologists to make earlier treatment decisions.